Welcome to our dedicated page for PMV Pharmaceuticals news (Ticker: PMVP), a resource for investors and traders seeking the latest updates and insights on PMV Pharmaceuticals stock.
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) is a pioneering precision oncology company headquartered in Cranbury, New Jersey. Established in 2013 and formerly known as PJ Pharmaceuticals, Inc., PMV Pharmaceuticals focuses on the discovery and development of small molecule therapies specifically targeting p53 mutations, which are prevalent in approximately 50% of all human cancers.
The company’s lead product candidate, PC14586, also known as Rezatapopt, is a small molecule designed to correct and restore the function of the p53 protein. This investigational therapy has shown significant promise in addressing the TP53 Y220C mutation, which is found in about 1% of all solid tumors. The U.S. Food and Drug Administration (FDA) has granted Rezatapopt Fast Track designation for treating locally advanced or metastatic solid tumors with a TP53 Y220C mutation.
In addition to PC14586, PMV Pharmaceuticals is developing other product candidates aimed at different p53 hotspot mutations, including the p53 R273H mutation. The company is actively engaged in the PYNNACLE Phase 2 clinical trial, a registrational, tumor-agnostic trial designed to evaluate the efficacy of Rezatapopt across various cancer types.
PMV Pharmaceuticals collaborates with leading institutions like Foundation Medicine to leverage comprehensive genomic profiling for better targeting and treatment of cancer patients. Foundation Medicine’s FDA-approved tests, such as FoundationOne CDx, play a crucial role in identifying patients who may benefit from PMV Pharma’s therapies.
Financially, PMV Pharmaceuticals has reported significant milestones, including the initiation of global trials and advancements in their therapeutic pipeline. The company remains committed to transforming cancer treatment through innovative oncology solutions.
Latest News:
- Third Quarter 2023 and Recent Corporate Highlights: Media Contact: Kathy Vincent, Greig Communications (kathy@greigcommunications.com)
- PRINCETON, N.J., May 09, 2024 - PMV Pharmaceuticals reports Q1 2024 financial results and provides a corporate update.
- PMV Pharma collaborates with Foundation Medicine to develop Rezatapopt, aiming to offer new therapeutic options for high unmet medical needs.
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) announced progress in its Phase 1/2 PYNNACLE study of PC14586, aimed at advanced solid tumors with a p53 Y220C mutation. The company has enrolled the first patient in a combination study with KEYTRUDA. As of December 31, 2022, PMV reported cash and equivalents of $243.5 million, a decline from $314.1 million in 2021, with a net loss of $73.3 million for the year compared to a loss of $57.8 million in 2021. R&D expenses increased to $52.0 million, mainly due to expanding clinical efforts. The firm continues to focus on PC14586 and expects further updates in the second half of 2023.
FAQ
What is the current stock price of PMV Pharmaceuticals (PMVP)?
What is the market cap of PMV Pharmaceuticals (PMVP)?
What does PMV Pharmaceuticals, Inc. specialize in?
What is the company's lead product candidate?
What specific mutations does PMV Pharmaceuticals target?
Has the FDA recognized any of PMV Pharmaceuticals' therapies?
What is the PYNNACLE Phase 2 clinical trial?
What collaborations has PMV Pharmaceuticals established?
Where is PMV Pharmaceuticals headquartered?
When was PMV Pharmaceuticals founded?
What recent milestones has the company achieved?
Who should I contact for more information about PMV Pharmaceuticals?
